REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot115510.21518/1561-5936-2019-11-8-15Original ArticleQuantitative of the Russian pharmaceutical manufacturers and their classificationTrofimovaElena O.noemail@neicon.ruYasinskayaLolita E.noemail@neicon.ruSaint Petersburg State Chemopharmaceutical Academy111220191181518032022Copyright © 2019,2019Background. The active growth of the Russian pharmaceutical industry has actualized the study of business models implemented by representatives of the industry. A key element of the business models of pharmaceutical manufacturers is their product portfolio, which has both qualitative and quantitative characteristics. Objective of the study is a quantitative analysis of the product portfolios of Russian pharmaceutical manufacturers and their classification according to the degree of diversification. Research methodology. The study was conducted using IQVIA data on Russian manufacturers having at least 500 million rubles for their sales at the domestic market in 2018. The analysis included a step-by-step scoring of the nomenclature width and sales concentration in the context of three elements - pharmacotherapeutic groups, INN, SKU. Results. The portfolios classification (21 options) was obtained using a three-digit «code» composed of points characterizing the degree of portfolio diversification in the context of three elements of analysis. As a result of summing up the points of the three-digit «code», a rating of companies was formed, on the base of which three groups of manufacturers were identified by the degree of portfolio diversification. Conclusion. The classification of product portfolios obtained as a result of their quantitative analysis can be used as one of the elements for describing business models, as well as for the most general assessment of commercial risks which are specific for representatives of the Russian pharmaceutical industry.pharmaceutical manufacturersthe Russian pharmaceutical marketproduct portfolioproduct diversificationbusiness modelфармацевтические производителироссийский фармацевтический рынокпродуктовый портфельдиверсифицированность номенклатуры производствабизнес-модель1.Кравченко Н.А., Юсупова А.Т. Российские фармацевтические компании: бизнес-модели лидеров рынка. Вопросы экономики. 2019;(8):127-138. doi: 10.32609/0042-8736-2019-8-127-138.2.Климанов Д.Е., Третьяк О.А. Использование сетевого подхода к анализу бизнес-модели: пример российского фармацевтического рынка. Российский журнал менеджмента. 2019;14 (2):77-100. doi: 10.21638/11701/spbu18.2016.204.3.Климанов Д.Е., Третьяк О А. Бизнес-модели: основные направления исследований и поиски содержательного фундамента концепции. Российский журнал менеджмента. 2014;12 (3):107-130. Режим доступа: https://rjm.spbu.ru/article/view/199.4.Остервальдер А., Пинье И. Построение бизнес-моделей. Настольная книга стратега и новатора. М.: Альпина Паблишер; 2018. 288 с.5.Edmunds R., Pisani J., Strang D. Pharma's identity crisis. Four strategies for creating value in life sciences. Strategy+Business. 2016, June 15. Available at: https://www.strategy-business.com/article/ Pharmas-Identity-Crisis?gko=ac347.6.Edmunds R., Pisani J., Strang D., Swanick M. Beyond 2020: Building Strategic Coherence in the New Health Economy. Pharmaceutical Executive, March 2016. Available at: https://www. pwc.com/vn/en/industries/assets/beyond-2020.pdf.7.Kravchenko N.A., Yusupova A.T. Russian pharmaceutical companies: Business models of market leaders. Voprosy Ekonomiki. 2019;(8):127-138. (In Russ.) doi: 10.32609/0042-8736-2019-8-127138.8.Klimanov D.E., Tretyak O.A. Application of a Network-Based Approach for Business Model Analysis: The Example of Russian Pharmaceutical Market. Rossiyskiy zhurnal menedzhmenta = Russian Management Journal. 2019;14 (2):77-100. (In Russ.) doi: 10.21638/11701/spbu18.2016.204.9.Klimanov D.E., Tretyak O.A. Business Models: Major Research Directions and Search of Conceptual Foundations. Rossiyskiy zhurnal menedzhmenta = Russian Management Journal. 2014;12 (3):107-130. (In Russ.) Available at: https://rjm.spbu.ru/article/view/199.10.Osterwalder A., Pigneur Y. (2018). Building business models. Handbook of the strategist and innovator. Moscow: Alpina Publisher; 2018. 288 с.11.Edmunds R., Pisani J., Strang D. Pharma's identity crisis. Four strategies for creating value in life sciences. Strategy+Business. 2016, June 15. Available at: https://www.strategy-business.com/article/ Pharmas-Identity-Crisis?gko=ac347.12.Edmunds R., Pisani J., Strang D., Swanick M. Beyond 2020: Building Strategic Coherence in the New Health Economy. Pharmaceutical Executive, March 2016. Available at: https://www. pwc.com/vn/en/industries/assets/beyond-2020.pdf.